title: Oxidative injury to erythrocytes, cell rigidity and splenic hemolysis in hemodialyzed patients before and during erythropoietin treatment.
abstract: The oxidative injury to erythrocytes, red blood cell (RBC) rigidity and splenic hemolysis was assayed in 17 chronically hemodialyzed patients before and during recombinant erythropoietin (EPO) treatment. When a stable hematocrit between 30 and 35% had been established for at least 4 months, a statistically significant increase in RBC volume, hemoglobin concentration, hematocrit, reticulocyte count, and several RBC enzymes (2,3-diphosphoglycerate, glucose 6-phosphate dehydrogenase, pyruvate kinase, hexokinase) was noted. This indicated significant RBC rejuvenation under the influence of EPO. However, no significant improvement in the RBC oxidative sensitivity, RBC deformability, splenic RBC volume, slow mixing splenic RBC volume, and the intrasplenic RBC transit time could be disclosed. These data confirm the existence of an extra-erythrocytic factor in uremic plasma, which is partly responsible for a reduced RBC life span in hemodialysis patients despite EPO treatment.
authors.affiliation: Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium.
authors.forename: P
authors.initials: P
authors.lastname: Zachée
authors.forename: A
authors.initials: A
authors.lastname: Ferrant
authors.forename: R
authors.initials: R
authors.lastname: Daelemans
authors.forename: L
authors.initials: L
authors.lastname: Coolen
authors.forename: W
authors.initials: W
authors.lastname: Goossens
authors.forename: R L
authors.initials: RL
authors.lastname: Lins
authors.forename: M
authors.initials: M
authors.lastname: Couttenye
authors.forename: M E
authors.initials: ME
authors.lastname: De Broe
authors.forename: M A
authors.initials: MA
authors.lastname: Boogaerts
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000097:blood / Q000209:etiology; D004905:Erythrocyte Aging / Q000187:drug effects; D004907:Erythrocyte Deformability / Q000187:drug effects* / Q000502:physiology; D004912:Erythrocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D004920:Erythropoiesis / Q000187:drug effects; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006400:Hematocrit; D006461:Hemolysis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D017382:Reactive Oxygen Species / Q000378:metabolism; D006435:Renal Dialysis / Q000009:adverse effects*; D012680:Sensitivity and Specificity; D013154:Spleen / Q000166:cytology / Q000187:drug effects; D014511:Uremia / Q000097:blood
chemical_list: D017382:Reactive Oxygen Species; D004921:Erythropoietin